Refreshing results…
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis
UploadAML refractory to primary induction with Ida-FLAG has a poor clinical outcome
UploadPacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
UploadMissing publications? Search for publications with a matching author name.